CD66e (CEACAM5) Antibody, anti-human, REAdye_lease™
Synonyms: CEA, CEACAM5, Carcinoembryonic antigen
RECOMBINANT
Bioz Star94/100 Bioz rating
1 Citation
Clone:
REA876
Type of antibody:
Primary antibodies, Recombinant antibodies, Releasable antibodies
Isotype:
recombinant human IgG1
Applications:
MICS, IF, IHC Glossary
External link icon

Related products for CD66e (CEACAM5) Antibody, anti-human, REAdye_lease™

Specifications for CD66e (CEACAM5) Antibody, anti-human, REAdye_lease™
Overview

Clone REA876 recognizes the human CD66e (CEACAM5) antigen, a member of the immunoglobin superfamily which is also known as carcinoembryonic antigen (CEA) or CEA-related cell adhesion molecules 5 (CEACAM5). CD66e is GPI-linked glycosylated protein found in adenocarcinomas of endodermally derived digestive system epithelium and fetal colon. CD66e and other CEACAMs are host receptors for the Dr family of adhesins of Escherichia coli. CD66e is an intercellular adhesion molecule and is able to inhibit cellular differentiation. The overexpression of CD66e is used as an indicator for tumor invasiveness.

Clone REA876 is a full-length recombinant antibody, conjugated to a releasable fluorophore.

Alternative names

CEA, CEACAM5, Carcinoembryonic antigen

Detailed product information

Technical specifications

Clone
REA876
Clonality
monoclonal
Isotype
recombinant human IgG1
Isotype control
REA Control Antibody (S), human IgG1
Host
human cell line
Type of antibody
Primary antibodies, Recombinant antibodies, Releasable antibodies
Species reactivity
human
Antigen
CD66e (CEACAM5)
Distribution of antigen
epithelial cells

Recombinant antibodies at Miltenyi Biotec

As an innovation-powered company with a commitment to quality and excellence, Miltenyi Biotec applies cutting-edge methods to discover and develop newer and better antibodies to satisfy both market demand and regulatory requirements.

The Miltenyi way of generating best-in-class antibodies and antibody conjugates

At Miltenyi Biotec, we opt for recombinant antibodies, which enable sequence verification and optimization for lot-to-lot consistency, making them superior to hybridoma-based antibodies.

Infusing our unique expertise

Recombinants are the result of combining genetic material from different immunized animals, and using display technologies to screen in-house antibody libraries for the best antibodies. Additional analyses on existing hybridoma-based antibodies can also give rise to sequences contributing to novel recombinants.

Maximizing value for your research

By further re-engineering these antibody sequences, we can precisely control their properties to achieve the following benefits:

reduce undesirable binding to Fc gamma receptors,

  • eliminate destabilizing amino acid motifs,
  • increase specific bonding affinity for stronger, more accurate targeting, and
  • optimize fluorochrome conjugation for brighter and clearer signals.

In a final step, by synthesizing and cloning the resulting gene sequence, we achieve an expression vector that develops a cell line, which in turn produces a special recombinant antibody.

Better science with quality antibodies

Already in 2015, 100 of the world’s leading scientists collectively called for better standards and reproducibility in antibody production, proposing recombinant antibodies to circumvent variability (Baker, M. Reproducibility crisis: Blame it on the antibodies. Nature 521, 274–276 (2015). https://doi.org/10.1038/521274a). Moreover, by applying reverse engineering, which is encouraged by the EU Directive 2016/943 r, Miltenyi Biotec acts “[i]n the interest of innovation and fostering competition…” (§16).

Resources for CD66e (CEACAM5) Antibody, anti-human, REAdye_lease™
Certificates

To access a Certificate of Analysis (CoA) follow the link below and enter the specific lot of your product.

Get certificate

Should you wish to request additional documentation, such as a Safety Data Sheet (SDS) in other languages than English or Swedish, an SDS-replacement document, or a Certificate of Origin (CoO), please direct your inquiry to your local technical support team.

Contact technical support